The Fly

Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports

The U.S. Supreme Court rebuffed a bid by Bristol-Myers’ (BMY) Juno Therapeutics to reinstate a $1.2B award it won in its patent fight with Gilead Sciences’ (GILD) subsidiary Kite Pharma over the lymphoma drug Yescarta, reported Reuters’ Blake Brittain and Andrew Chung. A jury awarded the plaintiffs $778M in damages, which a judge later increased to $1.2B, but the U.S. Court of Appeals for the Federal Circuit threw out the award last year, the report noted. Reference Link

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More